Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
ArteraAI logo — A leading precision medicine company, Artera develops AI-ena...

ArteraAI

A leading precision medicine company, Artera develops AI-enabled tests to help personalize therapy for cancer patients.

Founded 2021 United States Los Altos, United States 114 employees Venture round Total: $110.00M AI, Biotechnology +2

General Information

Company Name ArteraAI
Founded Year 2021
Location United States Los Altos, United States
Employees 114
Industries AI, Biotechnology, Health Care +1
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with ArteraAI. To contact ArteraAI, visit artera.ai.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About ArteraAI

ArteraAI, established in 2021, is carving out a niche within the precision medicine landscape. Rooted in the intersection of AI, Biotechnology, Health Care, and Life Sciences, the company is headquartered in the United States.

The company's slogan, "A leading precision medicine company, Artera develops AI-enabled tests to help personalize therapy for cancer patients," encapsulates its mission. The AI technology developed by ArteraAI leverages data from five Phase III randomized trials to create prognostic and predictive AI biomarkers, particularly focusing on localized prostate cancer. This innovation suggests a profound capability to not only predict patient outcomes but also tailor treatments accordingly.

In terms of funding, ArteraAI recently secured a $20.00M Venture Round on 01 February 2024, with participation from a diverse group of investors including EDBI, Walden Catalyst, Prosperity7 Ventures, and others.

Taxonomy: precision medicine, AI-enabled tests, personalized therapy, cancer, prostate cancer, biomarkers, Phase III trials, medical AI, patient outcomes, treatment personalization

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $20.00M 9
EDBI Walden Catalyst Prosperity7 Ventures
EDBI, Walden Catalyst +7
01 Feb 2024
Venture Round $90.00M 1
Coatue
Coatue
21 Mar 2023

Latest News

View All
FDA approved AI device that predicts cancer prognosis — Qz.com
FDA approved AI device that predicts cancer prognosis
Qz.com Nov 23, 2025

ArteraAI Alternatives & Competitors

View All Alternatives
ArteraAI vs
Viewpoint Molecular Targeting, Inc.
Viewpoint Molecular Targeting, Inc. United States

Targeted α-Particle Radiotherapy for Cancer

Grant
10 employees
Biotechnology, Health Care
ArteraAI vs
Pear Bio
Pear Bio United Kingdom

Patient-centered cancer precision medicine

Series A
8 employees
Biotechnology, Health Care
ArteraAI vs
Aniling
Aniling Spain

Accelerating Epigenomics for Precision Medicine against cancer

Seed
12 employees
Biotechnology, Health Care
View all alternatives

FAQ About ArteraAI

A leading precision medicine company, Artera develops AI-enabled tests to help personalize therapy for cancer patients.
ArteraAI was founded in 2021.
ArteraAI is headquartered in Los Altos, United States.
ArteraAI operates in AI, Biotechnology, Health Care and Life Sciences. Its work centres on precision medicine, AI-enabled tests, personalized therapy and cancer.
ArteraAI has approximately 114 employees.
ArteraAI has completed 2 funding rounds, raising a total of $110.00M. The latest funding stage is Venture round.
Top alternatives and competitors to ArteraAI include Viewpoint Molecular Targeting, Inc., Pear Bio, Aniling, Cvergenx, Madison Vaccines. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ArteraAI and Viewpoint Molecular Targeting, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ArteraAI, https://bouncewatch.com/company/arteraai, updated 14 November 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes